Overview

NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Rouen
Treatments:
Botulinum Toxins